Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2018

02.07.2018 | Breast Oncology

Effect of Primary Breast Tumor Location on Axillary Nodal Positivity

verfasst von: Amita A. Desai, MD, Tanya L. Hoskin, MS, Courtney N. Day, BS, Elizabeth B. Habermann, PhD, Judy C. Boughey, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Variables such as tumor size, histology, and grade, tumor biology, presence of lymphovascular invasion, and patient age have been shown to impact likelihood of nodal positivity. The aim of this study is to determine whether primary location of invasive disease within the breast is associated with nodal positivity.

Patients and Methods

Patients with invasive breast cancer undergoing axillary staging from 2010 to 2014 were identified from the National Cancer Data Base. Rates of axillary nodal positivity by primary tumor locations were compared, and multivariable analysis performed using logistic regression to control for factors known to impact nodal positivity.

Results

A total of 599,722 patients met inclusion criteria. Likelihood of nodal positivity was greatest with primary tumors located in the nipple (43.8%), followed by multicentric disease (40.8%), central breast lesions (39.4%), and axillary tail lesions (38.4%). Tumor location remained independently associated with nodal positivity on multivariable analysis adjusting for variables known to affect nodal positivity with odds ratio 2.8 for tumors in the nipple [95% confidence interval (CI) 2.5–3.1], 2.2 for central breast (95% CI: 2.2–2.3), and 2.7 for axillary tail (95% CI: 2.4–2.9). When restricted to patients with clinically negative nodes (n = 430,949), a similar association was seen.

Conclusion

Patients with invasive breast cancer located in the nipple, central breast, and axillary tail have the highest risk of positive axillary lymph nodes independent of patient age, tumor grade, biologic subtype, histology, and size. This should be considered along with other factors in preoperative counseling and decision-making regarding plans for axillary lymph node staging.
Literatur
1.
Zurück zum Zitat Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247(2):207–13.CrossRefPubMed Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247(2):207–13.CrossRefPubMed
2.
Zurück zum Zitat Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252(3):426–32; (discussion 432–3). Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252(3):426–32; (discussion 432–3).
3.
Zurück zum Zitat Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15(12):1303–10.CrossRefPubMedPubMedCentral Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014; 15(12):1303–10.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Ansari B, Morton MJ, Adamczyk DL, et al. Distance of breast cancer from the skin and nipple impacts axillary nodal metastases. Ann Surg Oncol 2011; 18(11):3174–80.CrossRefPubMed Ansari B, Morton MJ, Adamczyk DL, et al. Distance of breast cancer from the skin and nipple impacts axillary nodal metastases. Ann Surg Oncol 2011; 18(11):3174–80.CrossRefPubMed
5.
Zurück zum Zitat Bevilacqua JL, Kattan MW, Fey JV, Cody HS 3rd, Borgen PI, Van Zee KJ. Doctor, What are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 2007; 25(24):3670–9.CrossRefPubMed Bevilacqua JL, Kattan MW, Fey JV, Cody HS 3rd, Borgen PI, Van Zee KJ. Doctor, What are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol 2007; 25(24):3670–9.CrossRefPubMed
6.
Zurück zum Zitat Chen K, Liu J, Li S, Jacobs L. Development of nomograms to predict axillary lymph node status in breast cancer patients. BMC Cancer 2017; 17(1):561.CrossRefPubMedPubMedCentral Chen K, Liu J, Li S, Jacobs L. Development of nomograms to predict axillary lymph node status in breast cancer patients. BMC Cancer 2017; 17(1):561.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Dihge L, Bendahl PO, Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg 2017; 104(11):1494–505.CrossRefPubMedPubMedCentral Dihge L, Bendahl PO, Ryden L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. Br J Surg 2017; 104(11):1494–505.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999; 230(5):692–6.CrossRefPubMedPubMedCentral Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999; 230(5):692–6.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000; 191(1):1–6 (discussion 6–8). Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000; 191(1):1–6 (discussion 6–8).
10.
Zurück zum Zitat Cunningham JE, Jurj AL, Oman L, Stonerock AE, Nitcheva DK, Cupples TE. Is risk of axillary lymph node metastasis associated with proximity of breast cancer to the skin? Breast Cancer Res Treat 2006; 100(3):319–28.CrossRefPubMed Cunningham JE, Jurj AL, Oman L, Stonerock AE, Nitcheva DK, Cupples TE. Is risk of axillary lymph node metastasis associated with proximity of breast cancer to the skin? Breast Cancer Res Treat 2006; 100(3):319–28.CrossRefPubMed
12.
Zurück zum Zitat Torstenson T. Shah-Khan MG, Hoskin TL, et al. Novel factors to improve prediction of nodal positivity in patients with clinical T1/T2 breast cancers. Ann Surg Oncol 2013; 20(10):3286–93.CrossRefPubMed Torstenson T. Shah-Khan MG, Hoskin TL, et al. Novel factors to improve prediction of nodal positivity in patients with clinical T1/T2 breast cancers. Ann Surg Oncol 2013; 20(10):3286–93.CrossRefPubMed
13.
Zurück zum Zitat Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer 2015; 121(24):4333–40.CrossRefPubMed Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer 2015; 121(24):4333–40.CrossRefPubMed
14.
Zurück zum Zitat Fernandez-Gonzalez S, Falo C, Pia MJ, et al. The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results, and the advantages and disadvantages of both procedures. Clin Breast Cancer 2018; 18(1):71–77.CrossRefPubMed Fernandez-Gonzalez S, Falo C, Pia MJ, et al. The shift from sentinel lymph node biopsy performed either before or after neoadjuvant systemic therapy in the clinical negative nodes of breast cancer patients. Results, and the advantages and disadvantages of both procedures. Clin Breast Cancer 2018; 18(1):71–77.CrossRefPubMed
15.
Zurück zum Zitat Sohn VY, Arthurs ZM, Sebesta JA, Brown TA. Primary tumor location impacts breast cancer survival. Am J Surg 2008; 195(5):641–4.CrossRefPubMed Sohn VY, Arthurs ZM, Sebesta JA, Brown TA. Primary tumor location impacts breast cancer survival. Am J Surg 2008; 195(5):641–4.CrossRefPubMed
16.
Zurück zum Zitat Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast cancer prognosis. Int J Cancer 2003; 105(4):542–5.CrossRefPubMed Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast cancer prognosis. Int J Cancer 2003; 105(4):542–5.CrossRefPubMed
Metadaten
Titel
Effect of Primary Breast Tumor Location on Axillary Nodal Positivity
verfasst von
Amita A. Desai, MD
Tanya L. Hoskin, MS
Courtney N. Day, BS
Elizabeth B. Habermann, PhD
Judy C. Boughey, MD
Publikationsdatum
02.07.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6590-7

Weitere Artikel der Ausgabe 10/2018

Annals of Surgical Oncology 10/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.